Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
暂无分享，去创建一个
Y. Im | A. Fasolo | R. Tiedt | T. Bachelot | U. Stammberger | S. Tolaney | Shiling Ruan | E. Calvo | A. Forero-Torres | S. C. Lee | Yen-Shen Lu | E. Hamilton | M. Maur | A. Abdelhady | L. Nardi